phenomenon against long-circulating liposomes upon repeated administration. Int. J. Pharm.
456(1), 235–242 (2013)
83. P. Zhang, F. Sun, S. Liu, S. Jiang, Anti-PEG antibodies in the clinic: current issues and
beyond PEGylation. J. Control Release 244, 184–193 (2016)
84. Y. Mima, A.S. Abu Lila, T. Shimizu, M. Ukawa, H. Ando, Y. Kurata et al., Ganglioside
inserted into PEGylated liposome attenuates anti-PEG immunity. J. Control Release 250, 20–
26 (2017)
85. T. Moro, Y. Takatori, K. Ishihara, T. Konno, Y. Takigawa, T. Matsushita et al., Surface
grafting of artificial joints with a biocompatible polymer for preventing periprosthetic
osteolysis. Nat. Mater. 3(11), 829–836 (2004)
86. S. Jiang, Z. Cao, Ultralow-fouling, functionalizable, and hydrolyzable zwitterionic materials
and their derivatives for biological applications. Adv. Mater. 22(9), 920–932 (2010)
87. P. Zhang, F. Sun, C. Tsao et al., Zwitterionic gel encapsulation promotes protein stability,
enhances pharmacokinetics, and reduces immunogenicity. Proc. Natl. Acad. Sci. U.S.A. 112
(39), 12046–12051 (2015)
88. V. Schellenberger, C.W. Wang, N.C. Geething, B.J. Spink, A. Campbell, W. To et al., A
recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable
manner. Nat. Biotechnol. 27(12), 1186–1190 (2009)
89. N.C. Geething, W. To, B.J. Spink, M.D. Scholle, C.W. Wang, Y. Yin et al., Gcg-XTEN: an
improved glucagon capable of preventing hypoglycemia without increasing baseline blood
glucose. PLoS ONE 5(4), e10175 (2010)
90. J.L. Cleland, N.C. Geething, J.A. Moore, B.C. Rogers, B.J. Spink, C.W. Wang et al., A novel
long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and
half-life. J. Pharm. Sci. 101(8), 2744–2754 (2012)
91. S.E. Alters, B. McLaughlin, B. Spink, T. Lachinyan, C.W. Wang, V. Podust et al.,
GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat
Crohn’s disease model. PLoS ONE 7(11), e50630 (2012)
388
A. S. Abu Lila and T. Ishida
456(1), 235–242 (2013)
83. P. Zhang, F. Sun, S. Liu, S. Jiang, Anti-PEG antibodies in the clinic: current issues and
beyond PEGylation. J. Control Release 244, 184–193 (2016)
84. Y. Mima, A.S. Abu Lila, T. Shimizu, M. Ukawa, H. Ando, Y. Kurata et al., Ganglioside
inserted into PEGylated liposome attenuates anti-PEG immunity. J. Control Release 250, 20–
26 (2017)
85. T. Moro, Y. Takatori, K. Ishihara, T. Konno, Y. Takigawa, T. Matsushita et al., Surface
grafting of artificial joints with a biocompatible polymer for preventing periprosthetic
osteolysis. Nat. Mater. 3(11), 829–836 (2004)
86. S. Jiang, Z. Cao, Ultralow-fouling, functionalizable, and hydrolyzable zwitterionic materials
and their derivatives for biological applications. Adv. Mater. 22(9), 920–932 (2010)
87. P. Zhang, F. Sun, C. Tsao et al., Zwitterionic gel encapsulation promotes protein stability,
enhances pharmacokinetics, and reduces immunogenicity. Proc. Natl. Acad. Sci. U.S.A. 112
(39), 12046–12051 (2015)
88. V. Schellenberger, C.W. Wang, N.C. Geething, B.J. Spink, A. Campbell, W. To et al., A
recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable
manner. Nat. Biotechnol. 27(12), 1186–1190 (2009)
89. N.C. Geething, W. To, B.J. Spink, M.D. Scholle, C.W. Wang, Y. Yin et al., Gcg-XTEN: an
improved glucagon capable of preventing hypoglycemia without increasing baseline blood
glucose. PLoS ONE 5(4), e10175 (2010)
90. J.L. Cleland, N.C. Geething, J.A. Moore, B.C. Rogers, B.J. Spink, C.W. Wang et al., A novel
long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and
half-life. J. Pharm. Sci. 101(8), 2744–2754 (2012)
91. S.E. Alters, B. McLaughlin, B. Spink, T. Lachinyan, C.W. Wang, V. Podust et al.,
GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat
Crohn’s disease model. PLoS ONE 7(11), e50630 (2012)
388
A. S. Abu Lila and T. Ishida